Loading...

ASH 2024 Updates Will Validate Clinical Proof Of Concept

Published
16 Apr 25
Updated
01 May 25
AnalystConsensusTarget's Fair Value
US$12.58
100.0% undervalued intrinsic discount
20 May
US$0.0001
Loading
1Y
-100.0%
7D
0%

Author's Valuation

US$12.58100.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 0.40%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on24 Apr 25
Fair value Increased 3k%

AnalystConsensusTarget has increased revenue growth from -35.0% to 44.4%, increased profit margin from 12.3% to 16.8%, increased future PE multiple from 44.2x to 101.0x, decreased discount rate from 10.4% to 8.3% and increased shares outstanding growth rate from 0.0% to 0.1%.